Ablynx
Development of Nanobodies, proprietary therapeutic proteins.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD6.6b (Public information from Jan 2018)
Company register number 0475.295.446
Ghent East Flanders (HQ)
Financials
Estimates*
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
---|---|---|---|---|---|---|
Revenues | 100m | 200m | 200m | 200m | 200m | 200m |
% growth | - | 100 % | - | - | - | - |
EBITDA | - | 100m | 60.0m | 40.0m | 70.0m | 80.0m |
% EBITDA margin | - | 50 % | 30 % | 20 % | 35 % | 40 % |
R&D budget | - | - | 33.0m | - | - | - |
R&D % of revenue | - | - | 17 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Spinout | ||
€5.0m | Series A | ||
€25.0m | Series B | ||
$50.0m | Series C | ||
N/A | N/A | IPO | |
N/A | $31.5m | Post IPO Equity | |
N/A | €41.7m | Post IPO Equity | |
N/A | $83.0m | Post IPO Equity | |
N/A | $82.8m | Post IPO Equity | |
* | N/A | $150m | Post IPO Equity |
* | €3.9b Valuation: €3.9b 19.5x EV/LTM Revenues 65.0x EV/LTM EBITDA | Acquisition | |
Total Funding | AUD128m |
Related Content
Recent News about Ablynx
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.